{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:45:47Z","timestamp":1792183547972,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anthracyclines are a cornerstone of cancer therapy, yet they carry a significant risk of cardiotoxicity, which may present as subclinical myocardial injury or overt heart failure. Timely detection is essential to prevent irreversible cardiac dysfunction and safeguard long-term quality of life. Cardiac magnetic resonance (CMR) imaging\u2014capable of quantifying myocardial structure, function, and tissue characteristics\u2014has emerged as a leading modality in this context. This systematic review evaluates the role of CMR in detecting both early and late cardiotoxic changes after anthracycline exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a systematic search in accordance with PRISMA 2020 guidelines, searching PubMed, Embase, Scopus and Web of Science for studies involving CMR assessment in patients treated with anthracyclines. We extracted data on changes in functional parameters, volumetric indices, strain measurements, and tissue characterization before, during, and after anthracycline therapy in patients receiving active chemotherapy, and differences of these parameters compare to healthy adults or their pretreatment CMR scan in long term cancer survivors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across the 26 eligible studies, CMR consistently identified early declines in left ventricular ejection fraction, often before changes were detectable on echocardiography. More sensitive markers, including increases in the left ventricular end-systolic volume and alterations in strain parameters, provided early signs of subclinical dysfunction. Tissue mapping techniques revealed significant increases in native T1, T2, and extracellular volume (ECV), correlating with diffuse myocardial injury, even in the absence of late gadolinium enhancement. In long-term survivors, persistent abnormalities in strain and ECV were observed, highlighting the enduring nature of anthracycline induced cardiotoxicity. Right ventricular and left atrial remodeling, while less frequently assessed, emerged as clinically relevant and prognostically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CMR is a promising noninvasive tool that enables early detection and monitoring of anthracycline-induced cardiotoxicity, aiding risk stratification and timely cardioprotective interventions in cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12880-025-02027-y","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:49:59Z","timestamp":1763549399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beyond ejection fraction: cardiac magnetic resonance imaging in anthracycline cardiotoxicity"],"prefix":"10.1186","volume":"25","author":[{"given":"Marzieh","family":"Motevalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tourisa","family":"Deilami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5796-2049","authenticated-orcid":false,"given":"Yasmin Mohtasham","family":"Kia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Poopak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Houshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"1","key":"2027_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14\u201325.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 7","key":"2027_CR2","doi-asserted-by":"publisher","first-page":"vii173","DOI":"10.1093\/annonc\/mdq295","volume":"21","author":"I Brana","year":"2010","unstructured":"Brana I, Tabernero J, Cardiotoxicity. Ann Oncol. 2010;21(Suppl 7):vii173\u20139.","journal-title":"Ann Oncol"},{"issue":"9","key":"2027_CR3","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the heart failure association (HFA), the European association of cardiovascular imaging (EACVI) and the Cardio-Oncology Council of the European society of cardiology (ESC). Eur J Heart Fail. 2020;22(9):1504\u201324.","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"2027_CR4","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS): developed by the task force on cardio-oncology of the European society of cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"key":"2027_CR5","doi-asserted-by":"crossref","unstructured":"Mabudian L, Jordan JH, Bottinor W, Hundley WG. Cardiac MRI assessment of anthracycline-induced cardiotoxicity. Front Cardiovasc Med. 2022;9:2022.","DOI":"10.3389\/fcvm.2022.903719"},{"key":"2027_CR6","unstructured":"Venkatesh P, Kasi A. Anthracyclines, in StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Anup Kasi declares no relevant financial relationships with ineligible companies.: StatPearls Publishing."},{"key":"2027_CR7","doi-asserted-by":"crossref","unstructured":"Safaei AM, Kamangar TM, Asadian S, Rezaeian N, Esmati E, Kolahdouzan K, et al. Detection of the early cardiotoxic effects of doxorubicin-containing chemotherapy regimens in patients with breast cancer through novel cardiac magnetic resonance imaging: a short-term follow-up. J Clin Imaging Sci. 11:33.","DOI":"10.25259\/JCIS_58_2021"},{"key":"2027_CR8","doi-asserted-by":"crossref","unstructured":"Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7.","DOI":"10.3389\/fcvm.2020.00026"},{"issue":"8","key":"2027_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41569-025-01126-1","volume":"22","author":"I Fabiani","year":"2025","unstructured":"Fabiani I, Chianca M, Cipolla CM, Cardinale DM. Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment. Nat Rev Cardiol. 2025;22(8):551\u201363.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"2027_CR10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/annonc\/mdq543","volume":"22","author":"N Harbeck","year":"2011","unstructured":"Harbeck N, Ewer MS, De Laurentiis M, Suter TM, Ewer SM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol. 2011;22(6):1250\u20138.","journal-title":"Ann Oncol"},{"key":"2027_CR11","doi-asserted-by":"publisher","first-page":"b4606","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ. 2009;339:b4606.","journal-title":"BMJ"},{"issue":"2","key":"2027_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jama.2010.923","volume":"304","author":"RC Reulen","year":"2010","unstructured":"Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long-term Cause-Specific mortality among survivors of childhood cancer. JAMA. 2010;304(2):172\u20139.","journal-title":"JAMA"},{"issue":"2","key":"2027_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jaccao.2020.04.011","volume":"2","author":"I Harries","year":"2020","unstructured":"Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, et al. Magnetic resonance imaging to detect cardiovascular effects of cancer therapy: JACC cardiooncology State-of-the-Art review. JACC CardioOncol. 2020;2(2):270\u201392.","journal-title":"JACC CardioOncol"},{"issue":"9","key":"2027_CR14","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","volume":"107","author":"H Sawaya","year":"2011","unstructured":"Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375\u201380.","journal-title":"Am J Cardiol"},{"key":"2027_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2027_CR16","doi-asserted-by":"crossref","unstructured":"Ferreira de Souza T, Quinaglia AC, Silva T, Osorio Costa F, Shah R, Neilan TG, Velloso L, et al. Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC: Cardiovascular Imaging. 2018;11(8):1045\u201355.","DOI":"10.1016\/j.jcmg.2018.05.012"},{"key":"2027_CR17","doi-asserted-by":"crossref","unstructured":"Toro-Salazar OH, Lee JH, Zellars KN, Perreault PE, Mason KC, Wang Z, et al. Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines. Cardiooncology. 2018;4.","DOI":"10.1186\/s40959-018-0030-5"},{"key":"2027_CR18","doi-asserted-by":"crossref","unstructured":"Altaha MA, Nolan M, Marwick TH, Somerset E, Houbois C, Amir E, et al. Can quantitative CMR tissue characterization adequately identify cardiotoxicity during chemotherapy? Impact of temporal and observer variability. JACC: Cardiovascular Imaging. 2020;13(4):951\u201362.","DOI":"10.1016\/j.jcmg.2019.10.016"},{"issue":"1","key":"2027_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1055\/s-0039-1697921","volume":"29","author":"T Tak","year":"2020","unstructured":"Tak T, Jaekel CM, Gharacholou SM, Dworak MW, Marshall SA. Measurement of ejection fraction by cardiac magnetic resonance imaging and echocardiography to monitor Doxorubicin-Induced cardiotoxicity. Int J Angiol. 2020;29(1):45\u201351.","journal-title":"Int J Angiol"},{"issue":"11","key":"2027_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","volume":"106","author":"J Lambert","year":"2020","unstructured":"Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart. 2020;106(11):817\u201323.","journal-title":"Heart"},{"issue":"6","key":"2027_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1067\/mhj.2001.115436","volume":"141","author":"R Wassmuth","year":"2001","unstructured":"Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001;141(6):1007\u201313.","journal-title":"Am Heart J"},{"issue":"2","key":"2027_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/imj.12645","volume":"45","author":"S Grover","year":"2015","unstructured":"Grover S, Lou PW, Bradbrook C, Cheong K, Kotasek D, Leong DP, et al. Early and late changes in markers of aortic stiffness with breast cancer therapy. Intern Med J. 2015;45(2):140\u20137.","journal-title":"Intern Med J"},{"issue":"5","key":"2027_CR23","doi-asserted-by":"publisher","first-page":"e008777","DOI":"10.1161\/CIRCIMAGING.118.008777","volume":"12","author":"MB Lustberg","year":"2019","unstructured":"Lustberg MB, Reinbolt R, Addison D, Ruppert AS, Moore S, Carothers S, et al. Early detection of Anthracycline-Induced cardiotoxicity in breast cancer survivors with T2 cardiac magnetic resonance. Circ Cardiovasc Imaging. 2019;12(5):e008777.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"2027_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","volume":"9","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J - Cardiovasc Pharmacotherapy. 2023;9(6):515\u201325.","journal-title":"Eur Heart J - Cardiovasc Pharmacotherapy"},{"issue":"5","key":"2027_CR25","first-page":"962","volume":"14","author":"CP Houbois","year":"2021","unstructured":"Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, et al. Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography. JACC: Cardiovasc Imaging. 2021;14(5):962\u201374.","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"6","key":"2027_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/RTI.0000000000000285","volume":"32","author":"E Avelar","year":"2017","unstructured":"Avelar E, Truong QA, Inyangetor D, Marfatia R, Yang C, Kaloudis E, et al. Effect of adjuvant chemotherapy on left ventricular remodeling in women with newly diagnosed primary breast cancer. J Thorac Imaging. 2017;32(6):365\u20139.","journal-title":"J Thorac Imaging"},{"issue":"5","key":"2027_CR27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/pbc.25381","volume":"62","author":"M de Ville de Goyet","year":"2015","unstructured":"de Ville de Goyet M, Brichard B, Robert A, Renard L, Veyckemans F, Vanhoutte L, et al. Prospective cardiac MRI for the analysis of biventricular function in children undergoing cancer treatments. Pediatr Blood Cancer. 2015;62(5):867\u201374.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2027_CR28","doi-asserted-by":"publisher","first-page":"17132","DOI":"10.1038\/s41598-021-96630-y","volume":"11","author":"TF de Souza","year":"2021","unstructured":"de Souza TF, Silva TQ, Antunes-Correa L, Drobni ZD, Costa FO, Dertkigil SSJ, et al. Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy. Sci Rep. 2021;11(1):17132.","journal-title":"Sci Rep"},{"key":"2027_CR29","doi-asserted-by":"crossref","unstructured":"Li X, Shen H, Peng Y, Miao Z, Tu C, Zhang X et al. The additional value of myocardial T1\u03c1 mapping to T1 and T2 mapping for predicting subsequent cancer therapy-related cardiac dysfunction in breast cancer patients who received anthracyclines with\/without trastuzumab. Eur J Radiol. 2024;181.","DOI":"10.1016\/j.ejrad.2024.111755"},{"issue":"6","key":"2027_CR30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamacardio.2023.0494","volume":"8","author":"P Thavendiranathan","year":"2023","unstructured":"Thavendiranathan P, Shalmon T, Fan CPS, Houbois C, Amir E, Thevakumaran Y, et al. Comprehensive cardiovascular magnetic resonance tissue characterization and cardiotoxicity in women with breast cancer. JAMA Cardiol. 2023;8(6):524\u201334.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2027_CR31","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00330-021-08260-7","volume":"32","author":"E Tahir","year":"2022","unstructured":"Tahir E, Azar M, Shihada S, Seiffert K, Goy Y, Beitzen-Heineke A, et al. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT. Eur Radiol. 2022;32(3):1853\u201365.","journal-title":"Eur Radiol"},{"issue":"8","key":"2027_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-016-0533-x","volume":"18","author":"KL Nguyen","year":"2016","unstructured":"Nguyen KL, Hu P, Ennis DB, Shao J, Pham KA, Chen JJ. Cardiac MRI: a translational imaging tool for characterizing Anthracycline-Induced myocardial remodeling. Curr Oncol Rep. 2016;18(8):48.","journal-title":"Curr Oncol Rep"},{"key":"2027_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijcard.2018.03.025","volume":"261","author":"A Kimball","year":"2018","unstructured":"Kimball A, Patil S, Koczwara B, Raman KS, Perry R, Grover S, et al. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients. Int J Cardiol. 2018;261:159\u201361.","journal-title":"Int J Cardiol"},{"issue":"11","key":"2027_CR34","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/j.amjcard.2014.03.019","volume":"113","author":"K Yl\u00e4nen","year":"2014","unstructured":"Yl\u00e4nen K, Eerola A, Vettenranta K, Poutanen T. Three-dimensional echocardiography and cardiac magnetic resonance imaging in the screening of long-term survivors of childhood cancer after cardiotoxic therapy. Am J Cardiol. 2014;113(11):1886\u201392.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2027_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40959-019-0047-4","volume":"5","author":"TM Long","year":"2019","unstructured":"Long TM, Marsh CE, Dembo LG, Watson P, Wallman KE, Walwyn TS, et al. Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy. Cardio-Oncology. 2019;5(1):11.","journal-title":"Cardio-Oncology"},{"key":"2027_CR36","doi-asserted-by":"crossref","unstructured":"Tham EB, Haykowsky MJ, Chow K, Spavor M, Kaneko S, Khoo NS et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson. 2013;15(1).","DOI":"10.1186\/1532-429X-15-48"},{"key":"2027_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijcard.2021.08.037","volume":"343","author":"I Harries","year":"2021","unstructured":"Harries I, Berlot B, ffrench-Constant N, Williams M, Liang K, De Garate E, et al. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction. Int J Cardiol. 2021;343:180\u20136.","journal-title":"Int J Cardiol"},{"issue":"9","key":"2027_CR38","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/ehjci\/jeab137","volume":"23","author":"S Chhikara","year":"2022","unstructured":"Chhikara S, Hooks M, Athwal PSS, Hughes A, Ismail MF, Joppa S, et al. Long-term prognostic value of right ventricular dysfunction on cardiovascular magnetic resonance imaging in anthracycline-treated cancer survivors. Eur Heart J Cardiovasc Imaging. 2022;23(9):1222\u201330.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"2027_CR39","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1136\/jim-2020-001373","volume":"68","author":"D Mokshagundam","year":"2020","unstructured":"Mokshagundam D, Olivieri LJ, McCarter R, Kim A, Sable CA, Spurney CF, et al. Cardiac changes in pediatric cancer survivors. J Investig Med. 2020;68(8):1364\u20139.","journal-title":"J Investig Med"},{"key":"2027_CR40","doi-asserted-by":"crossref","unstructured":"Wolf CM, Reiner B, K\u00fchn A, Hager A, M\u00fcller J, Meierhofer C et al. Subclinical cardiac dysfunction in childhood cancer survivors on 10-Years Follow-Up correlates with cumulative anthracycline dose and is best detected by cardiopulmonary exercise Testing, Circulating serum Biomarker, speckle tracking Echocardiography, and tissue doppler imaging. Front Pead. 2020;8.","DOI":"10.3389\/fped.2020.00123"},{"issue":"11","key":"2027_CR41","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","volume":"110","author":"TG Neilan","year":"2012","unstructured":"Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol. 2012;110(11):1679\u201386.","journal-title":"Am J Cardiol"},{"issue":"14","key":"2027_CR42","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jacc.2013.01.019","volume":"61","author":"K Yl\u00e4nen","year":"2013","unstructured":"Yl\u00e4nen K, Poutanen T, Savikurki-Heikkil\u00e4 P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol. 2013;61(14):1539\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2027_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/ehjci\/jeaa279","volume":"22","author":"K Modi","year":"2021","unstructured":"Modi K, Joppa S, Chen KA, Athwal PSS, Okasha O, Velangi PS, et al. Myocardial damage assessed by late gadolinium enhancement on cardiovascular magnetic resonance imaging in cancer patients treated with anthracyclines and\/or trastuzumab. Eur Heart J Cardiovasc Imaging. 2021;22(4):427\u201334.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"2027_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.echo.2015.10.008","volume":"29","author":"OH Toro-Salazar","year":"2016","unstructured":"Toro-Salazar OH, Ferranti J, Lorenzoni R, Walling S, Mazur W, Raman SV, et al. Feasibility of echocardiographic techniques to detect subclinical cancer Therapeutics-Related cardiac dysfunction among High-Dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2016;29(2):119\u201331.","journal-title":"J Am Soc Echocardiogr"},{"issue":"6","key":"2027_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11864-018-0547-8","volume":"19","author":"S Jasra","year":"2018","unstructured":"Jasra S, Anampa J. Anthracycline use for early stage breast cancer in the modern era: a review. Curr Treat Options Oncol. 2018;19(6):30.","journal-title":"Curr Treat Options Oncol"},{"key":"2027_CR46","doi-asserted-by":"crossref","unstructured":"Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11(sup1):S21\u2013S36.","DOI":"10.1517\/14740338.2011.589834"},{"issue":"3","key":"2027_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tox.2010.03.012","volume":"271","author":"R L\u00fcpertz","year":"2010","unstructured":"L\u00fcpertz R, W\u00e4tjen W, Kahl R, Chovolou Y. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010;271(3):115\u201321.","journal-title":"Toxicology"},{"issue":"12","key":"2027_CR48","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ehjci\/jez232","volume":"20","author":"SE Petersen","year":"2019","unstructured":"Petersen SE, Khanji MY, Plein S, Lancellotti P, Bucciarelli-Ducci C. European association of cardiovascular imaging expert consensus paper: a comprehensive review of cardiovascular magnetic resonance normal values of cardiac chamber size and aortic root in adults and recommendations for grading severity. Eur Heart J Cardiovasc Imaging. 2019;20(12):1321\u201331.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"12","key":"2027_CR49","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.echo.2023.09.009","volume":"36","author":"L Mertens","year":"2023","unstructured":"Mertens L, Singh G, Armenian S, Chen MH, Dorfman AL, Garg R, et al. Multimodality imaging for cardiac surveillance of cancer treatment in children: recommendations from the American society of echocardiography. J Am Soc Echocardiogr. 2023;36(12):1227\u201353.","journal-title":"J Am Soc Echocardiogr"},{"key":"2027_CR50","doi-asserted-by":"crossref","unstructured":"Tham EB, Haykowsky MJ, Chow K, Kaneko S, Spavor M, Khoo NS et al. Diffuse myocardial fibrosis negatively correlates with exercise capacity in children with subclinical anthracycline cardiotoxicity. Circulation. 2011;124(21).","DOI":"10.1161\/circ.124.suppl_21.A9402"},{"key":"2027_CR51","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.15420\/ecr.2022.63","volume":"18","author":"DG Gent","year":"2023","unstructured":"Gent DG, Rebecca D. The 2022 European society of cardiology Cardio-oncology guidelines in focus. Eur Cardiol. 2023;18:e16.","journal-title":"Eur Cardiol"},{"issue":"5","key":"2027_CR52","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2024;6(5):655\u201377.","journal-title":"JACC CardioOncol"},{"issue":"4","key":"2027_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","volume":"85","author":"H null n, Drazner Mark","year":"2025","unstructured":"null n, Drazner Mark H, Bozkurt B, Cooper Leslie T, Aggarwal Niti R, Basso C, et al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis. JACC. 2025;85(4):391\u2013431.","journal-title":"JACC"},{"issue":"1","key":"2027_CR54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2478\/raon-2025-0012","volume":"59","author":"ESH Ibrahim","year":"2025","unstructured":"Ibrahim ESH, Chaudhary L, Cheng YC, Sosa A, An D, Charlson J. Cardiac MRI for differentiating chemotherapy-induced cardiotoxicity in sarcoma and breast cancer. Radiol Oncol. 2025;59(1):79\u201390.","journal-title":"Radiol Oncol"},{"key":"2027_CR55","doi-asserted-by":"crossref","unstructured":"Lustberg MB, Reinbolt R, Addison D, Ruppert AS, Moore S, Carothers S et al. Early detection of anthracycline-induced cardiotoxicity in breast cancer survivors with T2 cardiac magnetic resonance. Circ Cardiovasc Imaging. 2019;12(5).","DOI":"10.1161\/CIRCIMAGING.118.008777"},{"key":"2027_CR56","doi-asserted-by":"crossref","unstructured":"Long TM, Marsh CE, Dembo LG, Watson P, Wallman KE, Walwyn TS et al. Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy. Cardio-Oncology. 2019;5(1).","DOI":"10.1186\/s40959-019-0047-4"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-02027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-02027-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-02027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:12:58Z","timestamp":1781615578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12880-025-02027-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-02027-y","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"478"}}